FIGURE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Kaplan–Meier curves for the PFS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 3.51 for those with HCV-UN (vs. HCV-d), 95% CI: 1.58–7.78 (P = 0.002).